{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:13:48Z","timestamp":1788488028341,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Definitive treatment for aneurysmal subarachnoid hemorrhage (aSAH) includes microsurgical clipping and endovascular treatment (EVT). In randomized trials such as ISAT and BRAT, EVT showed superiority in short-term outcomes and comparable or favorable long-term results. Delayed cerebral ischemia is one of the most important determinants of clinical outcomes after treatment for aneurysmal subarachnoid hemorrhage caused by ruptured intracranial aneurysms. Although its pathophysiology is multifactorial, cerebral vasospasm has long been considered a major contributing factor. In Japan, fasudil has traditionally been used as a perioperative pharmacological agent for the prevention of cerebral vasospasm; since 2022, clazosentan has also become available. This study aimed to compare outcomes between clipping and EVT before and after the introduction of clazosentan in patients with aSAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using RECOVER registry data, we analyzed patients with aSAH who underwent definitive treatment with clipping or EVT within 48\u00a0h of onset and received either fasudil or clazosentan between 2021 and 2024. The primary endpoint was a favorable functional outcome at discharge, defined as a modified Rankin Scale (mRS) score of 0\u20132. Secondary endpoints included cerebral vasospasm, delayed cerebral ischemia (DCI), pulmonary complications, hypotension, cerebral edema, and new intracranial hemorrhage. In multivariable analyses, we adjusted for age, World Federation of Neurosurgical Societies (WFNS) grade, Fisher group, anterior circulation aneurysm, and the use of cerebrospinal fluid drainage. The study period was divided into the fasudil era and the clazosentan era, corresponding to the periods before and after the introduction of clazosentan, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 496 patients were analyzed, of whom 57.5% underwent microsurgical clipping. Overall, favorable outcomes at discharge, defined as an mRS score of 0\u20132, were significantly more frequent in the EVT group than in the clipping group (59.2% vs 48.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). In the fasudil era, the EVT group showed a higher proportion of favorable outcomes than the clipping group (59.0% vs 41.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), whereas no statistically significant between-group difference was observed in the clazosentan era (72.6% vs 62.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15). Among secondary outcomes, the incidence of vasospasm-related DCI was not significantly different between the groups, although it was numerically lower in the EVT group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Functional outcomes appeared more favorable in both the clipping and EVT groups during the clazosentan era. Across all study periods, the observed proportion of patients with favorable functional outcomes was higher in the EVT group than in the clipping group. However, because formal interaction testing did not identify statistically significant effect modification, the apparent reduction in between-group differences observed in the clazosentan era should be interpreted with caution and considered hypothesis-generating. Further prospective studies are needed to clarify the clinical relevance of these era-based observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10143-026-04469-6","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:45:22Z","timestamp":1788486322000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes before and after the introduction of clazosentan in aneurysmal subarachnoid hemorrhage: a multicenter retrospective study of clipping and endovascular treatment"],"prefix":"10.1007","volume":"49","author":[{"given":"Issei","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumie","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the RECOVER Study Collaborators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Maesawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Shimato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kinkori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hatano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyou","family":"Nakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamanouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigekazu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashige","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigemasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"issue":"11","key":"4469_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1161\/01.STR.25.11.2315","volume":"25","author":"MR Mayberg","year":"1994","unstructured":"Mayberg MR, Batjer HH, Dacey R et al (1994) Guidelines for the management of aneurysmal subarachnoid hemorrhage. Stroke 25(11):2315\u20132328. https:\/\/doi.org\/10.1161\/01.STR.25.11.2315","journal-title":"Stroke"},{"issue":"9342","key":"4469_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(02)11314-6","volume":"360","author":"AJ Molyneux","year":"2002","unstructured":"Molyneux AJ, Kerr R, Stratton I et al (2002) International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial. Lancet 360(9342):1267\u20131274. https:\/\/doi.org\/10.1016\/S0140-6736(02)11314-6","journal-title":"Lancet"},{"issue":"9488","key":"4469_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(05)67214-5","volume":"366","author":"AJ Molyneux","year":"2005","unstructured":"Molyneux AJ, Kerr RS, Yu LM et al (2005) International subarachnoid aneurysm trial (ISAT): a randomized comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 366(9488):809\u2013817. https:\/\/doi.org\/10.1016\/S0140-6736(05)67214-5","journal-title":"Lancet"},{"issue":"1","key":"4469_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3171\/2011.8.JNS101767","volume":"116","author":"CG McDougall","year":"2012","unstructured":"McDougall CG, Spetzler RF, Zabramski JM et al (2012) The barrow ruptured aneurysm trial. J Neurosurg 116(1):135\u2013144. https:\/\/doi.org\/10.3171\/2011.8.JNS101767","journal-title":"J Neurosurg"},{"issue":"5","key":"4469_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S1474-4422(09)70080-8","volume":"8","author":"AJ Molyneux","year":"2009","unstructured":"Molyneux AJ, Kerr RS, Birks J et al (2009) Risk of recurrent subarachnoid hemorrhage, death, or dependence after clipping or coiling of an intracranial aneurysm in the ISAT: long-term follow-up. Lancet Neurol 8(5):427\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(09)70080-8","journal-title":"Lancet Neurol"},{"issue":"9969","key":"4469_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0140-6736(14)60975-2","volume":"385","author":"AJ Molyneux","year":"2015","unstructured":"Molyneux AJ, Birks J, Clarke A et al (2015) Durability of endovascular coiling versus neurosurgical clipping: 18-year follow-up of the UK cohort of ISAT. Lancet 385(9969):691\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(14)60975-2","journal-title":"Lancet"},{"issue":"1","key":"4469_CR7","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3171\/2013.3.JNS12676","volume":"119","author":"RF Spetzler","year":"2013","unstructured":"Spetzler RF, McDougall CG, Albuquerque FC et al (2013) The barrow ruptured aneurysm trial: 3-year results. J Neurosurg 119(1):146\u2013157. https:\/\/doi.org\/10.3171\/2013.3.JNS12676","journal-title":"J Neurosurg"},{"issue":"1","key":"4469_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3171\/2016.10.JNS161376","volume":"128","author":"RF Spetzler","year":"2018","unstructured":"Spetzler RF, Zabramski JM, McDougall CG et al (2018) Analysis of sac and neck occlusion in the barrow ruptured aneurysm trial. J Neurosurg 128(1):120\u2013125. https:\/\/doi.org\/10.3171\/2016.10.JNS161376","journal-title":"J Neurosurg"},{"issue":"6","key":"4469_CR9","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3171\/2022.3.JNS212458","volume":"137","author":"H Endo","year":"2022","unstructured":"Endo H, Hagihara Y, Kimura N et al (2022) Effects of clazosentan on cerebral vasospasm\u2013related morbidity and all-cause mortality after aSAH: two randomized phase 3 trials in Japanese patients. J Neurosurg 137(6):1707\u20131717. https:\/\/doi.org\/10.3171\/2022.3.JNS212458","journal-title":"J Neurosurg"},{"key":"4469_CR10","doi-asserted-by":"publisher","DOI":"10.3171\/2024.3.JNS243009","author":"S Muraoka","year":"2024","unstructured":"Muraoka S, Izumi T, Nishida K et al (2024) RECOVER study: a multicenter retrospective cohort comparing clazosentan and fasudil in aSAH. J Neurosurg. https:\/\/doi.org\/10.3171\/2024.3.JNS243009","journal-title":"J Neurosurg"},{"issue":"9596","key":"4469_CR11","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M et al (2007) The STROBE statement: guidelines for reporting observational studies. Lancet 370(9596):1453\u20131457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet"},{"issue":"10","key":"4469_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1161\/STROKEAHA.110.589275","volume":"41","author":"MDI Vergouwen","year":"2010","unstructured":"Vergouwen MDI, Vermeulen M, van Gijn J et al (2010) Definition of delayed cerebral ischemia after aSAH: proposal of a multidisciplinary research group. Stroke 41(10):2391\u20132395. https:\/\/doi.org\/10.1161\/STROKEAHA.110.589275","journal-title":"Stroke"},{"issue":"11","key":"4469_CR13","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/jcbfm.2008.74","volume":"28","author":"MDI Vergouwen","year":"2008","unstructured":"Vergouwen MDI, Vermeulen M, Coert BA et al (2008) Microthrombosis after aSAH: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28(11):1761\u20131770. https:\/\/doi.org\/10.1038\/jcbfm.2008.74","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"4469_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3171\/jns.1996.84.3.0405","volume":"84","author":"FG Barker 2nd","year":"1996","unstructured":"Barker FG 2nd, Ogilvy CS (1996) Efficacy of prophylactic nimodipine for delayed ischemic deficit after SAH: a meta-analysis. J Neurosurg 84(3):405\u2013414. https:\/\/doi.org\/10.3171\/jns.1996.84.3.0405","journal-title":"J Neurosurg"},{"key":"4469_CR15","doi-asserted-by":"publisher","first-page":"CD000277","DOI":"10.1002\/14651858.CD000277","volume":"2","author":"GJE Rinkel","year":"2001","unstructured":"Rinkel GJE, Feigin VV, Algra A et al (2001) Calcium antagonists for aSAH. Cochrane Database Syst Rev. 2:CD000277. https:\/\/doi.org\/10.1002\/14651858.CD000277","journal-title":"Cochrane Database Syst Rev."},{"key":"4469_CR16","doi-asserted-by":"publisher","first-page":"CD000277","DOI":"10.1002\/14651858.CD000277.pub3","volume":"3","author":"S Dorhout Mees","year":"2007","unstructured":"Dorhout Mees S, Rinkel GJE, Feigin VL et al (2007) Calcium antagonists for aSAH. Cochrane Database Syst Rev. 3:CD000277. https:\/\/doi.org\/10.1002\/14651858.CD000277.pub3","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"4469_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.surneu.2006.10.037","volume":"68","author":"Y Suzuki","year":"2007","unstructured":"Suzuki Y, Shibuya M, Satoh S et al (2007) A post-marketing surveillance study of fasudil after aSAH. Surg Neurol 68(2):126\u2013132. https:\/\/doi.org\/10.1016\/j.surneu.2006.10.037","journal-title":"Surg Neurol"},{"issue":"4","key":"4469_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3171\/jns.1992.76.4.0571","volume":"76","author":"M Shibuya","year":"1992","unstructured":"Shibuya M, Suzuki Y, Sugita K et al (1992) Effect of AT877 on cerebral vasospasm after aSAH: a prospective placebo-controlled trial. J Neurosurg 76(4):571\u2013577. https:\/\/doi.org\/10.3171\/jns.1992.76.4.0571","journal-title":"J Neurosurg"},{"issue":"1","key":"4469_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.hest.2023.10.006","volume":"5","author":"H Suzuki","year":"2024","unstructured":"Suzuki H, Nakajima H, Ichikawa T et al (2024) Beneficial effects of clazosentan add-on treatment on delayed cerebral microcirculatory disturbances after aSAH. Brain Hemorrhages 5(1):62\u201368. https:\/\/doi.org\/10.1016\/j.hest.2023.10.006","journal-title":"Brain Hemorrhages"},{"key":"4469_CR20","doi-asserted-by":"publisher","first-page":"1413632","DOI":"10.3389\/fneur.2024.1413632","volume":"15","author":"H Sakata","year":"2024","unstructured":"Sakata H, Kanoke A, Uchida H et al (2024) Prophylactic management of cerebral vasospasm with clazosentan in real practice: a single-center cohort. Front Neurol 15:1413632. https:\/\/doi.org\/10.3389\/fneur.2024.1413632","journal-title":"Front Neurol"},{"key":"4469_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10143-023-02104-2","volume":"46","author":"S Muraoka","year":"2023","unstructured":"Muraoka S, Asai T, Fukui T et al (2023) Real-world data of clazosentan in combination therapy for aSAH: a multicenter cohort study. Neurosurg Rev 46:195. https:\/\/doi.org\/10.1007\/s10143-023-02104-2","journal-title":"Neurosurg Rev"},{"issue":"4","key":"4469_CR22","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00415-011-6243-2","volume":"259","author":"SM Dorhout Mees","year":"2012","unstructured":"Dorhout Mees SM, Kerr RS, Rinkel GJE, Algra A, Molyneux AJ (2012) Occurrence and impact of delayed cerebral ischemia after coiling and clipping in the International Subarachnoid Aneurysm Trial (ISAT). J Neurol 259(4):679\u2013683","journal-title":"J Neurol"},{"issue":"11","key":"4469_CR23","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1161\/STROKEAHA.108.519942","volume":"39","author":"RL Macdonald","year":"2008","unstructured":"Macdonald RL, Kassell NF, Mayer S et al (2008) CONSCIOUS-1 Investigators. Clazosentan to overcome ischemia after SAH (CONSCIOUS-1): randomized phase 2 trial. Stroke. 39(11):3015\u20133021. https:\/\/doi.org\/10.1161\/STROKEAHA.108.519942","journal-title":"Stroke."},{"issue":"7","key":"4469_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S1474-4422(11)70108-9","volume":"10","author":"RL Macdonald","year":"2011","unstructured":"Macdonald RL, Higashida RT, Keller E et al (2011) CONSCIOUS-2 Investigators. Clazosentan in patients with aSAH undergoing clipping: a randomized phase 3 trial (CONSCIOUS-2). Lancet Neurol. 10(7):618\u2013625. https:\/\/doi.org\/10.1016\/S1474-4422(11)70108-9","journal-title":"Lancet Neurol."},{"issue":"6","key":"4469_CR25","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/STROKEAHA.111.648980","volume":"43","author":"RL Macdonald","year":"2012","unstructured":"Macdonald RL, Higashida RT, Keller E et al (2012) CONSCIOUS-3 Investigators. Randomized trial of clazosentan in aSAH patients undergoing coiling (CONSCIOUS-3). Stroke. 43(6):1463\u20131469. https:\/\/doi.org\/10.1161\/STROKEAHA.111.648980","journal-title":"Stroke."},{"issue":"1","key":"4469_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3171\/2024.4.JNS232191","volume":"142","author":"SA Mayer","year":"2025","unstructured":"Mayer SA, Bruder N, Citerio G et al (2025) REACT Investigators. REACT: randomized trial of clazosentan for preventing deterioration due to DCI after aSAH. J Neurosurg. 142(1):98\u2013109. https:\/\/doi.org\/10.3171\/2024.4.JNS232191","journal-title":"J Neurosurg."},{"issue":"1\u20132","key":"4469_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1159\/000475824","volume":"44","author":"M Fujimura","year":"2017","unstructured":"Fujimura M, Joo JY, Kim JS et al (2017) Preventive effect of clazosentan against vasospasm after clipping for aSAH: multicenter, randomized phase II trial. Cerebrovasc Dis 44(1\u20132):59\u201367. https:\/\/doi.org\/10.1159\/000475824","journal-title":"Cerebrovasc Dis"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04469-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04469-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:45:23Z","timestamp":1788486323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04469-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4469"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04469-6","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nagoya University Hospital (approval number: 2022\u20130476) as a retrospective observational study using anonymized clinical data. Informed consent was obtained using an opt-out approach, whereby approved notifications were posted in the outpatient clinic and neurosurgical wards to provide an opportunity for patients to decline participation.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was waived due to the retrospective nature of the study, and consent was obtained using an opt-out method as approved by the institutional review board.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Nagoya University Hospital (approval number: 2022\u20130476).","order":3,"name":"Ethics","label":"Approval committee\/IRB","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"551"}}